Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.

Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of people of all ages living with cancer starting from the biology of childhood cancer. Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan.  It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies. Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA.

Day One Biopharmaceuticals

Senior Director, Drug Safety

Senior Director, Development Safety Operations

Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.

Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions.  Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

Vir Biotechnology

Senior Director, Global Pharmacovigilance & Risk Management Head of Medical Safety

Senior Director, Global Pharmacovigilance & Risk Management-Medical Safety

BeiGene is a life sciences, biotechnology company.

BeiGene is a clinical-stage Biopharma company focused on discovering and developing innovative, best-in-class, targeted and immuno-oncology drugs that address severe unmet medical needs in a variety of cancer indications.

BeiGene

Senior Director, Head of Safety Epidemiology

Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.

Lyell Immunopharma

Senior Director, Pharmacovigilance Operations

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer‚Äôs disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector‚Äôs strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

Alector

Senior Director, Nonclinical Science

Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.

Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. It pioneers in the field of Generative Biology, a revolutionary approach to drug development that allows them to program protein-based modalities for the first time. The company was founded in 2018 and is headquartered in Somerville, Massachusetts.

Location

Company Stage

Age of Data

Experience

Industry

Company

Senior Director, Drug Safety

Day One Biopharmaceuticals

$285k - $300k

$285,000 - $300,000

Vir Biotechnology

$225k - $290k

$225,262 - $289,750

BeiGene

$216k - $286k

$215,800 - $285,800

Lyell Immunopharma

$228k - $285k

$228,000 - $285,000

Alector

$262k - $283k

$262,080 - $283,466

Generate Biomedicines

N/A

N/A